NewAmsterdam Pharma (NASDAQ:NAMS) Given Consensus Rating of "Buy" by Brokerages

Shares of NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) have earned a consensus rating of "Buy" from the six ratings firms that are covering the firm, Marketbeat.com reports. Six investment analysts have rated the stock with a buy rating. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $43.33.

Several brokerages have recently weighed in on NAMS. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $40.00 target price on shares of NewAmsterdam Pharma in a research report on Friday, January 24th. UBS Group set a $41.00 price target on NewAmsterdam Pharma in a research report on Monday, March 3rd. Scotiabank increased their price objective on shares of NewAmsterdam Pharma from $47.00 to $52.00 and gave the company a "sector outperform" rating in a research report on Thursday, February 27th. Needham & Company LLC reissued a "buy" rating and set a $42.00 target price on shares of NewAmsterdam Pharma in a research report on Tuesday. Finally, HC Wainwright restated a "buy" rating and issued a $48.00 target price on shares of NewAmsterdam Pharma in a research note on Tuesday, January 14th.

NewAmsterdam Pharma Stock Performance

Shares of NASDAQ:NAMS traded down $1.31 during trading on Friday, reaching $14.55. 142,455 shares of the stock were exchanged, compared to its average volume of 577,959. NewAmsterdam Pharma has a 12-month low of $14.06 and a 12-month high of $27.29. The firm's 50-day moving average price is $20.51 and its 200 day moving average price is $21.26. The firm has a market cap of $1.60 billion, a price-to-earnings ratio of -5.61 and a beta of -0.01.

Remove Ads

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last released its quarterly earnings data on Wednesday, February 26th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.47). The firm had revenue of $12.77 million for the quarter, compared to the consensus estimate of $3.30 million. As a group, equities research analysts forecast that NewAmsterdam Pharma will post -1.75 EPS for the current year.

Insider Activity at NewAmsterdam Pharma

In other NewAmsterdam Pharma news, CAO Louise Frederika Kooij sold 150,000 shares of the firm's stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $20.37, for a total value of $3,055,500.00. Following the sale, the chief accounting officer now directly owns 15,000 shares in the company, valued at approximately $305,550. This trade represents a 90.91 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director James N. Topper purchased 1,135 shares of NewAmsterdam Pharma stock in a transaction dated Wednesday, March 26th. The shares were purchased at an average cost of $22.49 per share, with a total value of $25,526.15. Following the acquisition, the director now owns 3,013,569 shares of the company's stock, valued at approximately $67,775,166.81. This trade represents a 0.04 % increase in their position. The disclosure for this purchase can be found here. Insiders own 19.50% of the company's stock.

Institutional Trading of NewAmsterdam Pharma

Several hedge funds have recently bought and sold shares of the company. Frazier Life Sciences Management L.P. grew its position in NewAmsterdam Pharma by 23.8% in the 4th quarter. Frazier Life Sciences Management L.P. now owns 15,916,418 shares of the company's stock worth $409,052,000 after purchasing an additional 3,061,224 shares during the last quarter. Bain Capital Life Sciences Investors LLC grew its holdings in NewAmsterdam Pharma by 2.3% in the 4th quarter. Bain Capital Life Sciences Investors LLC now owns 10,719,110 shares of the company's stock worth $275,481,000 after buying an additional 245,197 shares in the last quarter. RA Capital Management L.P. raised its stake in NewAmsterdam Pharma by 9.7% during the 4th quarter. RA Capital Management L.P. now owns 8,845,000 shares of the company's stock valued at $227,316,000 after acquiring an additional 781,000 shares in the last quarter. Deerfield Management Company L.P. Series C grew its position in NewAmsterdam Pharma by 378.4% in the 4th quarter. Deerfield Management Company L.P. Series C now owns 4,314,340 shares of the company's stock valued at $110,879,000 after buying an additional 3,412,590 shares in the last quarter. Finally, Jennison Associates LLC grew its position in NewAmsterdam Pharma by 291.9% in the 4th quarter. Jennison Associates LLC now owns 3,998,541 shares of the company's stock valued at $102,763,000 after buying an additional 2,978,263 shares in the last quarter. 89.89% of the stock is currently owned by institutional investors.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.